Psychemedics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Brian Hullinger

Chief executive officer

US$973.4k

Total compensation

CEO salary percentage	12.9%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	1.8yrs

Recent management updates

Recent updates

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

Jan 08

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

May 13

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Aug 09

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

Apr 25

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Nov 18

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Oct 18

Psychemedics reports Q1 results

May 10

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

May 07

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Mar 05

Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)

Jan 30

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

Jan 11

Psychemedics reports Q3 results

Nov 09

CEO Compensation Analysis

How has Brian Hullinger's remuneration changed compared to Psychemedics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$973k	US$126k	-US$4m

Compensation vs Market: Brian's total compensation ($USD973.37K) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Insufficient data to compare Brian's compensation with company performance.

CEO

Brian Hullinger (55 yo)

less than a year

Tenure

US$973,370

Compensation

Mr. Brian Hullinger serves as President and Chief Executive Officer at Psychemedics Corporation since August 17, 2023. He served as Chief Revenue Officer at Cisive since 2019 until January 2023. From 2016...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Brian Hullinger	President	less than a year	US$973.37k	no data
Daniella Mehalik	Vice President of Finance	less than a year	US$126.41k	no data
Shannon Shoemaker	Chief Revenue Officer	less than a year	US$386.62k	no data
Werner Baumgartner	Founder	46.3yrs	no data	no data
Annette Baumgartner	Founder	46.3yrs	no data	no data
Michael Weisenhoff	Principal Financial & Accounting Manager	less than a year	no data	no data
Patrick Kinney	Secretary	no data	no data	no data

0.8yrs

Average Tenure

33yo

Average Age

Experienced Management: PMD's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Brian Hullinger	President	less than a year	US$973.37k	no data
Darius Nevin	Independent Chairman	1.8yrs	US$70.00k	0.078% $ 11.6k
Peter Kamin	Independent Director	1.8yrs	US$70.00k	10.06% $ 1.5m
Andrew Reynolds	Independent Director	2.1yrs	US$86.04k	0.12% $ 18.1k
Robyn Davis	Independent Director	3.2yrs	US$116.78k	0.33% $ 49.1k

1.8yrs

Average Tenure

61yo

Average Age

Experienced Board: PMD's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Psychemedics Management

Management criteria checks 0/4

Key information

Recent management updates

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

Psychemedics Corporation Announces Charles Doucot, to Leave as Executive Vice President, Effective September 15, 2023

High number of new and inexperienced directors

Executive Vice President recently sold US$59k worth of stock

Executive Vice President notifies of intention to sell stock

Psychemedics Corporation, Annual General Meeting, Aug 17, 2023

Recent updates

Full year 2023 earnings released: US$0.72 loss per share (vs US$0.19 loss in FY 2022)

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$0.017 loss in 3Q 2022)

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

Psychemedics Corporation Announces Charles Doucot, to Leave as Executive Vice President, Effective September 15, 2023

High number of new and inexperienced directors

Executive Vice President recently sold US$59k worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.06 loss in 2Q 2022)

New minor risk - Shareholder dilution

Psychemedics Corporation, Annual General Meeting, Aug 17, 2023

Psychemedics Corporation Announces Board Changes

Upcoming dividend of US$0.07 per share at 5.6% yield

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

First quarter 2023 earnings released: US$0.07 loss per share (vs US$0.007 profit in 1Q 2022)

Psychemedics Corporation Declares Cash Dividend, Payable on June 8, 2023

Full year 2022 earnings released: US$0.19 loss per share (vs US$0.12 loss in FY 2021)

Psychemedics Corporation Appoints William Norris as Controller of the Company, Effective as of January 1, 2023

Upcoming dividend of US$0.07 per share

Third quarter 2022 earnings released: US$0.017 loss per share (vs US$0.13 profit in 3Q 2021)

Third quarter 2022 earnings released: US$0.02 loss per share (vs US$0.13 profit in 3Q 2021)

Psychemedics Corporation Declares Quarterly Cash Dividend, Payable on December 16, 2022

Psychemedics Corporation Announces Executive Changes

Upcoming dividend of US$0.07 per share

Second quarter 2022 earnings released: US$0.06 loss per share (vs US$0.024 profit in 2Q 2021)

Psychemedics Corporation Announces Quarterly Dividend, Payable on September 9, 2022

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Psychemedics Corporation, Annual General Meeting, Aug 12, 2022

Upcoming dividend of US$0.07 per share

First quarter 2022 earnings: EPS exceeds analyst expectations

Psychemedics Corporation Declares Cash Dividend for First Quarter Ended March 31, 2022, Payable on June 24, 2022

Insider recently bought US$268k worth of stock

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

Insider recently bought US$268k worth of stock

Insider recently bought US$112k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Insider recently bought US$393k worth of stock

Psychemedics Corporation Enters into Binding Memorandum of Understanding to Settle Purported Class Action Lawsuit Against It Related to Certain California Wage and Hour Laws

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Third quarter 2021 earnings released: EPS US$0.13 (vs US$0.20 loss in 3Q 2020)

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Insider recently bought US$76k worth of stock

Insider recently bought US$728k worth of stock

Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.37 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.01 (vs US$0.029 loss in 1Q 2020)

Psychemedics reports Q1 results

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

Full year 2020 earnings released: US$0.70 loss per share (vs US$0.28 profit in FY 2019)

Psychemedics Corporation Elects Robyn C. Davis on the Board of Director, Effective Immediately

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

New 90-day high: US$7.45

Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)

Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller

New 90-day high: US$5.36

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

New 90-day high: US$5.14

Insider recently bought US$258k worth of stock

Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel

New 90-day high: US$4.95

Psychemedics Corporation Announces Resignation of Neil L. Lerner as Its Vice President-Finance, Treasurer and Assistant Secretary of the Corporation, Effective November 27, 2020

Third quarter 2020 earnings released: US$0.20 loss per share

Psychemedics reports Q3 results

New 90-day low: US$3.99

New 90-day low: US$4.30

New 90-day low: US$4.48

New 90-day low - US$4.53

Earnings released

New 90-day low - US$4.54